0.6689
Ovid Therapeutics Inc stock is traded at $0.6689, with a volume of 1.77M.
It is up +10.49% in the last 24 hours and up +115.50% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$0.6054
Open:
$0.658
24h Volume:
1.77M
Relative Volume:
1.31
Market Cap:
$47.57M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-0.8919
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+81.77%
1M Performance:
+115.50%
6M Performance:
-4.85%
1Y Performance:
-35.06%
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
OVID
Ovid Therapeutics Inc
|
0.6689 | 26.17M | 391.70K | -52.34M | -45.92M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
Apr-30-24 | Initiated | B. Riley Securities | Buy |
Apr-29-24 | Initiated | H.C. Wainwright | Buy |
Apr-05-24 | Initiated | Wedbush | Outperform |
Dec-21-23 | Initiated | BTIG Research | Buy |
Oct-13-23 | Initiated | Oppenheimer | Outperform |
Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Is Ovid Therapeutics Inc. a good long term investmentRapid wealth multiplication - jammulinksnews.com
July 2025's Top Penny Stocks To Watch - simplywall.st
What drives Ovid Therapeutics Inc. stock priceFree Capital Growth Strategies - printweek.in
What analysts say about Ovid Therapeutics Inc. stockPhenomenal returns - jammulinksnews.com
Ovid Therapeutics Stock Soars 13.88% on Investor Optimism - AInvest
Ovid Therapeutics Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
Ovid Therapeutics (NASDAQ:OVID) Receives Average Rating of “Buy” from Analysts - Defense World
Ovid Therapeutics (NASDAQ:OVID) Stock Rating Upgraded by Wall Street Zen - Defense World
What makes Ovid Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - beatles.ru
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Ovid Therapeutics Surges 25% Amid Analyst Hype and Strategic Pipeline Progress - AInvest
Why Ovid Therapeutics Inc. stock attracts strong analyst attentionDaily Breakout Picks - Newser
How Ovid Therapeutics Inc. stock performs during market volatilityTop Rated Trade Entries - Newser
Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World
Ovid Therapeutics Approves Key Proposals at Annual Meeting - The Globe and Mail
Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica - TipRanks
Balance Sheet Insights: Ovid Therapeutics Inc (OVID)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Stoke Therapeutics: Impressive Pipeline And Big Backers - Seeking Alpha
Ovid Therapeutics Inc (OVID) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier - insights.citeline.com
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Transcript : Ovid Therapeutics Inc.Special Call - MarketScreener
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results - mx.advfn.com
Ovid Therapeutics (OVID) to Showcase Biomarker Advances in Epile - GuruFocus
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 | OVID Stock News - GuruFocus
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 - GlobeNewswire
Harvard Expert to Present Breakthrough Epilepsy Treatment Data at Ovid Therapeutics Event - Stock Titan
Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Sold by BNP Paribas Financial Markets - Defense World
HC Wainwright Predicts Weaker Earnings for Ovid Therapeutics - Defense World
Ovid Therapeutics (NASDAQ:OVID) Price Target Cut to $1.50 by Analysts at HC Wainwright - Defense World
Ovid Therapeutics Reports Q1 2025 Financial Results - TipRanks
Ovid Therapeutics (OVID): HC Wainwright & Co. Lowers Price Targe - GuruFocus
Ovid Therapeutics (OVID): Price Target Revised Amid Future Growt - GuruFocus
Ovid Therapeutics (OVID): Price Target Revised Amid Future Growth Prospects | OVID Stock News - GuruFocus
Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) PT at $3.03 - Defense World
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):